Xience Sierra Coronary Stent
Device
Abbott Laboratories
Total Payments
$10.9M
Transactions
10,652
Doctors
2,437
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2021 | $10.5M | 6,471 | 1,353 |
| 2020 | $158,989 | 1,761 | 741 |
| 2019 | $236,537 | 966 | 459 |
| 2018 | $47,575 | 1,454 | 536 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $10.6M | 2,742 | 97.4% |
| Food and Beverage | $228,265 | 7,835 | 2.1% |
| Consulting Fee | $40,550 | 35 | 0.4% |
| Travel and Lodging | $5,477 | 26 | 0.1% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $3,950 | 4 | 0.0% |
| Charitable Contribution | $3,000 | 1 | 0.0% |
| Education | $763.69 | 9 | 0.0% |
Payments by Type
Research
$10.6M
2,742 transactions
General
$282,006
7,910 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Clinical TRIal to EvaLUate Cardiovascular OutcoMes IN PAtients Treated with the Tricuspid ValvE Repair System Pivotal | Abbott Laboratories | $3.4M | 0 |
| Clinical Trial to Evaluate the Safety and Effectiveness of Using the Tendyne Mitral Valve System for the Treatment of Symptomatic Mitral Regurgitation | Abbott Laboratories | $1.8M | 0 |
| CATALYST IDE Study | Abbott Laboratories | $1.1M | 0 |
| AMPLATZER Amulet Left Atrial Appendage Occluder Randomized Controlled Trial | Abbott Laboratories | $641,189 | 0 |
| PORTICO NG APPROVAL STUDY | Abbott Laboratories | $605,889 | 0 |
| Percutaneous MitraClipTM Device or Surgical Mitral Valve REpair in PAtients with PrImaRy MItral Regurgitation who are Candidates for Surgery (REPAIR MR) | Abbott Laboratories | $552,339 | 0 |
| Portico Re-sheathable Transcatheter Aortic Valve System US IDE Trial (PORTICO) | Abbott Laboratories | $532,051 | 0 |
| AMPLATZER PFO Occluder Post Approval Study | Abbott Laboratories | $512,309 | 0 |
| MitraClip EXPAND G4 Study | Abbott Laboratories | $441,866 | 0 |
| Abbott DBS Registry of Outcomes for Indications over Time | Abbott Laboratories | $199,519 | 0 |
| PARAvalvular leak closure with the Amplatzer valvular plug occluDer for Interventional transcatheter closure for chronic PVL with surgical bioloGical and Mechanical heart valve (Paradigm-PVL) | Abbott Laboratories | $129,898 | 0 |
| Acute Ex vivo thrombogenicity with dual and mono-anti platelet therapies | Abbott Laboratories | $90,076 | 0 |
| Portico Continued Access Protocol | Abbott Laboratories | $74,080 | 0 |
| In vitroHuman Platelet adhesion on Aspirin using fluorscent platelet coating: xience vs synergy vs onyx | Abbott Laboratories | $68,250 | 0 |
| Albumin Binding to competitive DES in a real time flow loop with confocal imaging (XIENCE, EluNIR, BMS) | Abbott Laboratories | $65,625 | 0 |
| The AMPLATZER Post-Infarct Muscular VSD Occluder Humanitarian Device Exemption (H070005) Post Approval Study | Abbott Laboratories | $49,107 | 0 |
| AMPLATZER Duct Occluder II Additional Sizes (ADO II AS) Clinical Study | Abbott Laboratories | $41,287 | 0 |
| A Contemporary, Prospective Study Evaluating Real-world Experience of Performance and Safety for the Next Generation of MitraClip Devices | Abbott Laboratories | $32,518 | 0 |
| Cephea Feasibility Study | Abbott Laboratories | $32,000 | 0 |
| Trial-Efficacy in a Rabbit Model | Abbott Laboratories | $29,698 | 0 |
Top Doctors Receiving Payments for Xience Sierra Coronary Stent
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Aakash Garg | — | Newark, NJ | $10.6M | 2,745 |
| , M.D | Cardiovascular Disease | Mountain View, CA | $29,100 | 24 |
| , MD | Internal Medicine | Baltimore, MD | $5,633 | 11 |
| , M.D | Internal Medicine | Gainesville, FL | $5,000 | 6 |
| , M.D | Interventional Cardiology | Kyle, TX | $2,930 | 33 |
| , MD | Cardiovascular Disease | Oklahoma City, OK | $2,742 | 4 |
| , M.D | Cardiovascular Disease | Beverly Hills, CA | $2,221 | 36 |
| , MD | Internal Medicine | Bronx, NY | $1,382 | 18 |
| , MD | Interventional Cardiology | Suffern, NY | $1,344 | 53 |
| Lance Kovar | — | West Nyack, NY | $1,241 | 49 |
| , M.D | Interventional Cardiology | Mineola, NY | $1,215 | 58 |
| , M.D | Internal Medicine | El Cajon, CA | $1,214 | 10 |
| Felix Rios Gonzalez | Specialist | Rio Piedras, PR | $1,200 | 3 |
| , M.D | Cardiovascular Disease | Hawthorne, NY | $1,173 | 57 |
| , M.D | Cardiovascular Disease | Edison, NJ | $1,111 | 43 |
| , MD | Cardiovascular Disease | Plainfield, NJ | $1,057 | 50 |
| , M.D | Cardiovascular Disease | Houston, TX | $1,031 | 10 |
| , MD | Emergency Medical Services | San Antonio, TX | $1,031 | 18 |
| , MD | Cardiovascular Disease | Middletown, NY | $1,001 | 48 |
| , MD | Interventional Cardiology | Mechanicsville, VA | $979.16 | 15 |
| , M.D | Cardiovascular Disease | San Diego, CA | $965.00 | 13 |
| , M.D | Critical Care Medicine | Bronx, NY | $936.22 | 11 |
| , MD | Interventional Cardiology | Philadelphia, PA | $890.59 | 24 |
| , M.D | Cardiovascular Disease | New York, NY | $840.41 | 37 |
| , M.D | Cardiovascular Disease | Philadelphia, PA | $836.61 | 26 |
Ad
Manufacturing Companies
- Abbott Laboratories $10.9M
Product Information
- Type Device
- Total Payments $10.9M
- Total Doctors 2,437
- Transactions 10,652
About Xience Sierra Coronary Stent
Xience Sierra Coronary Stent is a device associated with $10.9M in payments to 2,437 healthcare providers, recorded across 10,652 transactions in the CMS Open Payments database. The primary manufacturer is Abbott Laboratories.
Payment data is available from 2018 to 2021. In 2021, $10.5M was paid across 6,471 transactions to 1,353 doctors.
The most common payment nature for Xience Sierra Coronary Stent is "Unspecified" ($10.6M, 97.4% of total).
Xience Sierra Coronary Stent is associated with 20 research studies, including "Clinical TRIal to EvaLUate Cardiovascular OutcoMes IN PAtients Treated with the Tricuspid ValvE Repair System Pivotal" ($3.4M).